Medtronic Plc MDT has recalled certain implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) with glassed feedthrough.
The FDA has identified this as a Class I recall, the most serious type of recall. The use of these devices may cause serious injuries or death.
Medtronic’s ICDs and CRT-Ds are implantable cardiac devices that monitor and regulate heart rate and rhythm.
These devices automatically detect and treat life-threatening irregular heartbeats (arrhythmia) by producing an electric shock (cardioversion or defibrillation) to restore a normal heartbeat.
Some devices can also provide cardiac resynchronization therapy to treat heart failure.
Medtronic is recalling all ICDs and CRT-Ds, manufactured after 2017 with a glassed feedthrough, as they may deliver low or no energy output when high voltage therapy is needed due to inappropriate activation of the Short Circuit Protection (SCP) feature.
The issue is more likely for devices with a glassed feedthrough configured to deliver therapy in the AX>B delivered pathway.
A reduced-energy shock, or no shock at all, may fail to correct a life-threatening arrhythmia, which can lead to cardiac arrest, other serious injury, or death.
Medtronic has reported 28 incidents, 22 injuries, and no deaths for this issue.
The recall impacts around 350k devices distributed between Oct. 13, 2017-June 9, 2023.
In January, Medtronic recalled around 22,700 hemodialysis catheters due to a possible defect in the device’s hub that could result in leakages across the catheter’s tubes that could mix the arterial and venous blood, lead to increased recirculation and poor dialysis, or cause blood clots in the blood vessels.
Price Action: MDT shares are down 0.95% at $85.89 at the time of publication on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
